PharmaWatch is connected by Sequans' Monarch technology, enabling it to upload its vaccine temperature monitoring data to the portal every 5 minutes via a secure and reliable cellular LTE-M network transmission.
PharmaWatch monitors temperatures as low as minus 200 degrees Celsius and provides reporting data every five minutes, exceeding the safety requirements of the CDC for the transport, storage, and handling of Covid-19 vaccines.
PharmaWatch comes with sensors preconfigured for the required temperature ranges and can be self-installed in minutes. Its patented Virtual Temperature Buffering technology minimizes false alerts.
The connection to the cellular network is provided by Sequans Monarch GM01Q module, one of the most mature and proven LTE-M/NB-IoT connectivity solutions in the industry.
Monarch is designed and optimized for IoT, delivering ultra-low power consumption and global deployment capability, making it an ideal solution for IoT applications including sensors, meters and trackers.
The module includes an LTE-optimized transceiver and a complete Single-SKU RF front end, supporting global deployment. Monarch is certified by major operators all over the world.
AmericanPharma Technologies was founded in 2010 when three predecessor companies merged.
Today, its core product is PharmaWatch, an advanced environmental monitoring system.
It alleviates the difficulties inherent in manually monitoring multiple healthcare environments in multiple locations while automatically maintaining complete regulatory compliance.
PharmaWatch makes worry-free compliance, unparalleled patient safety, and complete customer satisfaction an affordable reality for the first time ever.
Sequans Communications S.A. (NYSE: SQNS) is a developer and provider of 5G and 4G chips and modules for massive, broadband, and critical IoT.
For 5G/4G massive IoT applications, Sequans provides a comprehensive product portfolio based on its flagship Monarch LTE-M/NB-IoT and Calliope Cat 1 chip platforms, featuring industry-leading low power consumption, a large set of integrated functionalities, and global deployment capability.
For 5G/4G broadband and critical IoT applications, Sequans offers a product portfolio based on its Cassiopeia Cat 4/Cat 6 4G and high-end Taurus 5G chip platforms, optimized for low-cost residential, enterprise, and industrial applications.
Founded in 2003, Sequans is based in Paris, France with additional offices in the United States, United Kingdom, Finland, Israel, Hong Kong, Singapore, Taiwan, South Korea, and China.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV